PV Bulletin

Technical Guidelines for Communication on Real-World Evidence Supporting the Extension of Pediatric Indications for Marketed Drugs (Draft for Comments)

The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population.

Primary source: Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

A draft guideline has been issued by the CDE outlining the framework for sponsors to use real-world evidence (RWE) when seeking to expand pediatric drug indications, highlighting the necessity for early discussions with the regulator on RWE study plans.

Why it matters

This change affects data collection and presentation for pediatric label extensions, potentially influencing the efficiency and speed of bringing pediatric drugs to market in China.

Action needed

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Consultation
Policy status
consultation
Publication date
2026-07-14
Policy change
The CDE is seeking public comments on a draft guideline regarding the use of real-world evidence (RWE) to support expanding drug indications for the pediatric population. It establishes a framework for communication between sponsors and the CDE to improve the efficiency of pediatric research.

Key changes

Provides technical considerations for using RWE data sources, study design, and data analysis to support pediatric label extensions. Emphasizes the need for early communication with CDE on RWE study plans.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsClinical DevelopmentPV Operations

PV impact

Affects how sponsors collect and present real-world safety and efficacy data for pediatric indication extensions in China.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 14, 2026

Full briefing

Practical implication

Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

The CDE draft guideline outlines a framework for using real-world evidence to support the extension of drug indications for pediatrics. It emphasizes the importance of early communication with the CDE and provides technical considerations for RWE data collection and analysis.

What changed: A draft guideline has been issued by the CDE outlining the framework for sponsors to use real-world evidence (RWE) when seeking to expand pediatric drug indications, highlighting the necessity for early discussions with the regulator on RWE study plans.

Why it matters: This change affects data collection and presentation for pediatric label extensions, potentially influencing the efficiency and speed of bringing pediatric drugs to market in China.

Practical implication: Sponsors must implement early communication strategies with the CDE regarding RWE study plans as a prerequisite for pediatric indication extension submissions.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Labeling#Safety Signals#policy-change#consultation#firecrawl-policy-agent#Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward